VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity

— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs and […]